Continue Reading With Our 7-Day Free Trial
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene therapy landscape. On November 25, the FDA approved a new version of the company’s blockbuster gene therapy Zolgensma, now branded as Itvisma, for patients with spinal muscular atrophy (SMA) aged two and older. Previously, Zolgensma was only available to infants under two. This regulatory greenlight doesn’t just expand access—it potentially unlocks a much larger patient population, with commercial, clinical, and strategic implications.
Novartis is pricing Itvisma at $2.59 million, a one-time treatment. Unlike chronic SMA drugs from Biogen and Roche that require ongoing dosing, this pricing strategy positions Novartis to argue long-term cost savings. Itvisma also uses a different delivery route—into the spinal fluid—which helps mitigate dosing risks in older kids and adults. The approval was based on a Phase 3 trial showing meaningful motor improvements. Itvisma’s arrival could cement Novartis as the leader in gene therapy—a field that’s had more setbacks than wins. Here’s how this all shakes out.
Expanding the Gene Therapy Beachhead
The Novartis gene therapy approval for Itvisma is more than just a label expansion—it’s a strategic reassertion of dominance in a fragile space. Gene therapy has long been the future of medicine, but so far, it’s been mostly promise and very little delivery. Pfizer’s recent withdrawal of a hemophilia gene therapy, after tepid demand, showed how commercially brittle this sector still is.
Now, Novartis has pulled off something rare: a second act for a gene therapy that already proved its worth. Zolgensma brought in $1.2 billion last year treating infants. Itvisma could add another $510 million by 2027, according to consensus estimates. More importantly, the two treatments use the same active ingredient but target different patient age groups, potentially extending the product lifecycle without additional molecule development.
This is a savvy move. Gene therapies face challenges in scaling because dosing older patients requires higher viral vector volumes—raising both cost and safety concerns. Itvisma sidesteps that by delivering the treatment intrathecally (via spinal fluid), avoiding a higher systemic viral load. That technical edge is what likely made the FDA approval possible for a broader age group—and it shows Novartis isn’t just chasing headlines. It’s solving real delivery problems.
The One-Time Price Tag Makes Economic Sense—Sort Of
At $2.59 million per dose, Itvisma’s sticker shock is real. But Novartis argues it’s a bargain in disguise. According to the company, Itvisma costs 35%–46% less than the 10-year price of chronic SMA therapies like Biogen’s Spinraza or Roche’s Evrysdi. Those require annual six-figure treatments for life. In contrast, Itvisma is a one-and-done injection.
The Novartis gene therapy approval opens up a broader pricing debate in biotech: Is a single high-cost therapy preferable to lifetime treatment costs? Payers have been skittish about upfront payments, but value-based models are slowly gaining traction. Novartis has experience here—Zolgensma was one of the first gene therapies to test outcomes-based reimbursement contracts.
That said, pricing remains a political and regulatory minefield. The Biden administration is pressuring for broader drug pricing reform, and Novartis generates nearly a third of its revenue in the U.S. branded drugs market. Even with this new treatment, pricing backlash could resurface. Also worth watching is whether insurers will balk at covering Itvisma for older children and adults where clinical outcomes data are thinner. The STEER trial supporting approval only included patients up to 17, but the FDA allowed expansion into adults based on extrapolated data. That’s a scientific judgment call—and a payer risk.
Pipeline Risk Remains Very Real
While the Novartis gene therapy approval for Itvisma strengthens the company’s market position, the broader pipeline story still carries plenty of question marks. Several of Novartis’ current blockbusters—Entresto, Tasigna, and Promacta—are facing patent cliffs within the next five years. The firm is counting on newer therapies like Fabhalta, Pluvicto, and Leqvio to offset those losses. But approvals and market adoption don’t always move in lockstep.
In the gene therapy space, failure rates are still high. Other drugmakers have seen programs stall due to safety concerns or limited demand. Pfizer’s pullback in hemophilia is a cautionary tale. Moreover, SMA is a rare disease market, and the patient pool narrows as you go up in age. Itvisma’s peak sales estimates are just over half a billion dollars by 2027. That’s good—but it won’t make up for multi-billion-dollar drugs going off-patent.
Then there’s the matter of ongoing R&D spend. Novartis continues to invest heavily, particularly in advanced modalities like radioligand and oligonucleotide therapies. That’s great for innovation, but it could temporarily depress margins. The company’s forward P/E ratio is currently 14.15x, and its EV/EBIT is 12.85x—respectable, but not cheap if new product growth falters. As always in pharma, execution will be key.
Regulatory and Market Uncertainty Still Lingers
Another reason to temper the excitement around the Novartis gene therapy approval is the increasingly tricky regulatory and market environment. While the FDA’s greenlight for Itvisma signals confidence in the platform, it also comes with risk. The agency expanded the label to include adults even though no adult patients were studied in the STEER trial. That could be a future liability if outcomes vary from the pediatric population.
In addition, the U.S. remains the linchpin for global gene therapy revenue—but also its most volatile market. Drug pricing reforms are accelerating, especially for high-cost specialty therapies. Any shift in government reimbursement or insurer resistance could derail sales momentum for Itvisma. Novartis’ U.S. exposure adds a layer of vulnerability, even though the company is less dependent on the U.S. than some peers.
Also, while Itvisma may have first-mover advantage in older SMA patients, competition is not far behind. Roche and Biogen are already entrenched in the SMA space, and both are exploring label expansions. If these competitors can match or exceed Itvisma’s efficacy with a more palatable price or administration route, Novartis could face a sudden market squeeze.
Add to that broader ESG risks—such as litigation or off-label marketing investigations—and the landscape feels less than secure. So while the news is positive, the future isn’t risk-free.
Final Thoughts: A Win, But Not Without Caveats
The Novartis gene therapy approval for Itvisma is a rare win in a bruised sector. It expands access to a life-changing therapy, extends the commercial life of Zolgensma, and reinforces Novartis’ leadership in genetic medicine. From a business strategy perspective, the move fits Novartis’ broader focus on high-margin branded therapies and cutting-edge modalities.
However, this is no silver bullet. The market opportunity, while meaningful, is still modest in the grand scheme of Novartis’ revenue base. Clinical data gaps, pricing scrutiny, and pipeline dependency all remain real challenges. Add to that macro risks around U.S. drug pricing and future ESG liabilities, and it’s clear this is a good—but measured—step forward.
On valuation, Novartis trades at 13.25x trailing EBIT and 17.85x trailing earnings, with a 3.3% dividend yield. These are reasonable multiples for a company with a wide moat and strong cash flows—but not a steal, especially if growth hits turbulence.
As far as biotech plays go, Itvisma gives Novartis more credibility and more options. But the path forward? Still paved with risk and recalibration.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
